Literature DB >> 22234795

Urinary calcium excretion and insulin resistance in patients with acromegaly.

Alexandre Braga Libório1, Patrícia R L Figueiredo, Renan M Montenegro Junior, Renan M Montenegro, Manoel R A Martins, Geraldo B Silva Junior, Ivna Aguiar Porto, José Italo Soares Mota, Elizabeth Daher.   

Abstract

BACKGROUND: Renal complications in acromegaly include glomerular hyperfiltration, insulin resistance, hypercalciuria and urolithiasis. The aim of this study was to investigate whether urinary calcium (U(Ca)) excretion is a direct consequence of growth hormone secretion or secondary to hyperfiltration and/or insulin resistance.
METHODS: We performed a cross-sectional study of 58 patients diagnosed with acromegaly. Demographic data were obtained, serum analysis was performed, including insulin-like growth factor (IGF)-1, and 24-h urine collection, to measure urinary protein excretion, U(Ca) and phosphate excretion, as well as fractional excretion of sodium and potassium. We also calculated the homeostasis model assessment of insulin resistance (HOMA-IR).
RESULTS: Patients were predominantly male (60.3%), and their mean age was 45.9 ± 14 years. Hypercalciuria was present in 24% of patients. Patients with higher HOMA-IR had higher IGF-1 levels, a trend toward higher body mass index and higher U(Ca) excretion. In univariate analysis, U(Ca) excretion was associated with HOMA-IR (r = 0.472, P = 0.001), phosphaturia (r = 0.457, P = 0.001), IGF-1 (r = 0.398, P = 0.002) and creatinine clearance (r = 0.394, P = 0.001). HOMA-IR and phosphaturia were independently associated with U(Ca) excretion. No independent associations were found between phosphaturia and HOMA-IR or IGF-1.
CONCLUSIONS: The present study revealed an association between hypercalciuria and insulin resistance in patients with acromegaly. Further studies are required to fully understand the pathogenesis of these abnormalities in patients with acromegaly.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234795     DOI: 10.1007/s11255-011-0116-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

1.  [Renal lithiasis in an acromegalic patient. Role of somatotropic hormone in the mechanism of hypercalciuria].

Authors:  H BRICAIRE; R TOURNEUR; L MOREAU; D BOUTELIER
Journal:  J Urol Nephrol (Paris)       Date:  1961 Jan-Feb

2.  The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission.

Authors:  Renata S Auriemma; Mariano Galdiero; Maria C De Martino; Monica De Leo; Ludovica F S Grasso; Pasquale Vitale; Alessia Cozzolino; Gaetano Lombardi; Annamaria Colao; Rosario Pivonello
Journal:  Eur J Endocrinol       Date:  2010-03-31       Impact factor: 6.664

3.  Metabolic factors for urolithiasis in acromegalic patients.

Authors:  I P Heilberg; M A Czepielewski; H Ajzen; O L Ramos; N Schor
Journal:  Braz J Med Biol Res       Date:  1991       Impact factor: 2.590

4.  Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome.

Authors:  Domenico Rendina; Gianpaolo De Filippo; Giorgia Zampa; Riccardo Muscariello; Giuseppe Mossetti; Pasquale Strazzullo
Journal:  Nephrol Dial Transplant       Date:  2010-11-04       Impact factor: 5.992

5.  Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome.

Authors:  Akinori Iba; Yasuo Kohjimoto; Takashi Mori; Tomomi Kuramoto; Satoshi Nishizawa; Reona Fujii; Yoshihito Nanpo; Nagahide Matsumura; Yasuyo Shintani; Takeshi Inagaki; Isao Hara
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

Review 6.  Etiologic aspects and management of acromegaly.

Authors:  Giselle F Taboada; Flávia R van Haute; Lívia L Corrêa; Alessandra F Casini; Mônica R Gadelha
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-01-23

7.  Effects of growth hormone on renal tubular handling of sodium in healthy humans.

Authors:  T K Hansen; J Møller; K Thomsen; E Frandsen; R Dall; J O Jørgensen; J S Christiansen
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

8.  Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.

Authors:  Peter Kamenicky; Say Viengchareun; Anne Blanchard; Geri Meduri; Philippe Zizzari; Martine Imbert-Teboul; Alain Doucet; Philippe Chanson; Marc Lombès
Journal:  Endocrinology       Date:  2008-04-03       Impact factor: 4.736

9.  Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.

Authors:  C Parkinson; M Kassem; L Heickendorff; A Flyvbjerg; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 10.  Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

Authors:  Gherardo Mazziotti; Irene Floriani; Stefania Bonadonna; Valter Torri; Philippe Chanson; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  3 in total

1.  Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Authors:  Alexandra A Povaliaeva; Viktor P Bogdanov; Artem Yu Zhukov; Ekaterina A Pigarova; Larisa K Dzeranova; Liudmila Ya Rozhinskaya; Galina A Mel'nichenko; Natalia G Mokrysheva
Journal:  Endocrine       Date:  2022-02-09       Impact factor: 3.633

2.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

3.  Vanishing hypercalciuric kidney stones after treating underlying acromegaly.

Authors:  Eline van der Valk; Tom Tobe; Aline Stades; Alex Muller
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.